title: [Resveratrol reduces inflammatory cytokines via inhibiting nuclear factor-κB and mitogen-activated protein kinase signal pathway in a rabbit atherosclerosis model].
abstract: OBJECTIVE
  Inflammation serves as the initial pathologic step of cardiovascular diseases including atherosclerosis. Resveratrol possesses many pharmacological properties including antioxidant, cardioprotective and anti-cancer effects. In this study, we investigate the anti-inflammatory effect and mechanisms of resveratrol in an atherosclerotic rabbit model.
  
  
  METHODS
  Rabbit were assigned to six groups (n = 10 each): control, high fat diet group, resveratrol low, medium and high dose groups, resveratrol pretreatment group. The serum tumor necrosis factor-α (TNF- α), interleukin-6 (IL-6) and interleukin-1β (IL-1β) were analyzed by Enzyme-linked immuno sorbent assay(ELISA). Phosphorylation levels of mitogen-activated protein kinases (MAPKs) cascades and NF-κB were determined by Western blot.
  
  
  RESULTS
  Compared with the control group, the expression of serum inflammatory factors IL-1β, IL-6, TNF-α were increased in high-fat group (all P < 0.05). Compared with high-fat group, the expressions of IL-6, IL-1β, TNF-α were significantly reduced in resveratrol low, medium, high dose groups and resveratrol pretreatment group (all P < 0.01), and this effect is dose-dependent. In addition, the NF-κB, p38MAPK, JNK, ERK1/2 protein phosphorylation in high-fat group were significantly upregulated compared with control group (P < 0.05), which (except ERK1/2 phosphorylation level) were significantly downregulated in resveratrol treatment group and resveratrol pretreatment group.
  
  
  CONCLUSIONS
  This study indicates that resveratrol reduces serum inflammatory cytokines in this atherosclerotic rabbit model via down-regulation phosphorylation of NF-κB, and MAPKs signaling, which might serve as the anti-inflammatory molecular basis of resveratrol.
authors.affiliation: Department of Cardiology, Second Affiliated Hospital of Preclinical Medicine College of Kunming Medical University, Kunming 650000, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Song
authors.forename: Wan-qiu
authors.initials: WQ
authors.lastname: Li
authors.forename: Jian-lin
authors.initials: JL
authors.lastname: Dou
authors.forename: Lin
authors.initials: L
authors.lastname: Li
authors.forename: Yan-jie
authors.initials: YJ
authors.lastname: Hu
authors.forename: Jia-zhi
authors.initials: JZ
authors.lastname: Guo
authors.forename: Di
authors.initials: D
authors.lastname: Lu
authors.forename: Ge
authors.initials: G
authors.lastname: Zhang
authors.affiliation: Email: sunlinkm@sina.com.
authors.forename: Lin
authors.initials: L
authors.lastname: Sun
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy / Q000378:metabolism*; D004195:Disease Models, Animal; D053583:Interleukin-1beta / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D010766:Phosphorylation; D011817:Rabbits; D000077185:Resveratrol; D015398:Signal Transduction / Q000187:drug effects*; D013267:Stilbenes / Q000494:pharmacology* / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D053583:Interleukin-1beta; D015850:Interleukin-6; D016328:NF-kappa B; D013267:Stilbenes; D014409:Tumor Necrosis Factor-alpha; D020928:Mitogen-Activated Protein Kinases; D000077185:Resveratrol